Orexin Side Effects: What Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician for any health decision. It summarises what published trials and reviews reported about adverse events linked to the orexin system, and it flags plainly where human data do not exist.

Two different things get called "orexin side effects"

Orexin A and orexin B — also known as hypocretin 1 and hypocretin 2 — are hypothalamic neuropeptides that signal through the OX1R and OX2R receptors and help sustain wakefulness. The published safety literature does not describe the peptide being given to people. It describes small molecules that interact with orexin receptors: dual orexin receptor antagonists developed as hypnotics, and more recently an OX2R-selective agonist studied in narcolepsy type 1. A narrative review traced the orexin discovery story through to the receptor antagonists brought forward for insomnia treatment (PMID 37086045).

That distinction matters for anyone reading adverse-event lists. Blocking orexin receptors and stimulating them would be expected to produce opposite-direction effects, and the reported adverse-event profiles in the literature reflect that: sedation-adjacent complaints on the antagonist side, wake-promoting complaints such as insomnia on the agonist side (PMID 40367374).

Orexin receptor antagonists: What Studies Report

Suvorexant, lemborexant and daridorexant are the orexin receptor antagonists that have been approved as prescription insomnia medicines in various jurisdictions. Because they have gone through regulated development programmes, most of the human adverse-event data in this area concern them.

Class-level tolerability described in reviews

A review of orexin receptor antagonists in insomnia described the mechanism of the class and discussed its clinical profile and tolerability considerations in comparison with older hypnotics (PMID 35972717). A broader pharmacology review of insomnia drugs beyond benzodiazepines set out how orexin antagonism differs mechanistically from GABA-A receptor modulation and how those mechanistic differences shaped the adverse effects described for each class (PMID 29487083). A French-language overview of insomnia pharmacotherapies also placed orexin receptor antagonists among the available drug options and summarised their benefit–risk framing alongside behavioural treatment (PMID 38551874).

Comparative safety across the three antagonists

A 2025 systematic review and network meta-analysis compared daridorexant, lemborexant and suvorexant in insomnia and evaluated both efficacy and safety endpoints across the randomised evidence base, rather than examining a single agent in isolation (PMID 40555730). A wider network meta-analysis of pharmacological treatments for insomnia in adults assessed tolerability as a co-primary concern alongside efficacy, including discontinuations attributed to adverse events across drug classes (PMID 36701954). Readers comparing these two analyses should note that network meta-analyses pool trials with different populations, durations and adverse-event definitions, so the researchers' comparative conclusions are indirect rather than head-to-head.

Daridorexant-specific adverse events

A 2022 review of daridorexant for insomnia summarised the phase 3 programme that studied 25 mg and 50 mg nightly doses and described the adverse events reported in those trials, including headache and somnolence (PMID 36045942). Nothing in that review framed adverse events as universal; the reported events were those recorded more often than on placebo in trial populations with insomnia disorder.

Long-term antagonist exposure: What Studies Report

Short trials cannot show what happens over a year. Two extension studies addressed that directly.

An extension study of long-term safety and tolerability in patients with insomnia disorder reported that nasopharyngitis and headache were the most frequent adverse events during extended daridorexant 25 mg and 50 mg treatment, and the study reported no evidence of rebound insomnia or withdrawal symptoms after treatment ended (PMID 36484969). A separate long-term study in Japanese patients with insomnia disorder reported safety and efficacy outcomes over extended daridorexant treatment and described no new safety signals emerging with longer exposure (PMID 39128336).

Extension studies carry a structural limitation the researchers themselves acknowledge: participants who tolerated the drug in the parent trial are the ones who continue, so long-term adverse-event rates can look lower than they would in an unselected population (PMID 36484969).

Orexin receptor agonists: What Studies Report

The newest human data run in the opposite pharmacological direction. A 2025 New England Journal of Medicine trial evaluated oveporexton, an oral OX2R-selective agonist, in narcolepsy type 1 — the condition characterised by loss of orexin-producing neurons — and the researchers reported adverse events including insomnia and urinary urgency among treated participants (PMID 40367374). Those events are mechanistically coherent for a wake-promoting agonist and are not interchangeable with the antagonist adverse-event list.

This is a single phase 3 programme in a specific patient population. The study did not evaluate the agonist in healthy volunteers, in insomnia, or in any performance or cognition context, so its adverse-event profile cannot be generalised beyond narcolepsy type 1 (PMID 40367374).

Where human safety data are absent

Across the studies cited on this page, none administered orexin-A or orexin-B peptide itself to humans by any route. The literature summarised here concerns receptor-targeting small molecules only (PMID 37086045, PMID 35972717). That absence is itself the finding: there is no clinical adverse-event dataset in the verified literature for exogenous orexin peptide, no established human exposure range, and therefore no basis in these papers for describing what peptide administration would do or how it would be tolerated. Statements that fill that gap are extrapolation, not evidence.

Research-grade orexin peptides that circulate in laboratory supply chains are research-use-only materials and are not approved human medicines in the United States or the European Union. That regulatory status is separate from the approval status of the prescription orexin receptor antagonists discussed above.

What each cited source examined

Populations discussed in the reviews

Older adults and people with neurodegenerative disease appear frequently in this literature because insomnia is common in both groups. A review of Alzheimer disease treatment covered pharmacological management across the disease course, including symptomatic management alongside disease-directed therapy (PMID 39620846). The orexin antagonist review similarly discussed how the class has been positioned relative to older sedative-hypnotics in patients for whom fall risk and next-day impairment are prominent clinical concerns (PMID 35972717).

Orexin signalling has also been discussed in psychiatric contexts. A review of generalised anxiety disorder pharmacotherapy catalogued current prescribing practice and future directions for drug development in that indication (PMID 37183813). Adverse-event data from insomnia trials do not automatically transfer to anxiety populations, which differ in comorbidity and concomitant medication.

How to read this evidence critically

• Indication-specific data. Adverse events reported in insomnia disorder trials describe that population, at the doses studied, for the durations studied (PMID 36045942).
• Direction of pharmacology. Antagonist and agonist adverse-event lists are not interchangeable; the agonist trial reported insomnia as an adverse event, which would be an on-target consequence of wake promotion (PMID 40367374).
• Indirect comparisons. Network meta-analyses rank agents statistically rather than testing them against each other directly (PMID 40555730).
• Selection in extensions. Long-term tolerability figures come from participants who already completed a parent trial (PMID 36484969).
• Silence is not safety. The absence of human data for exogenous orexin peptide means nothing has been characterised, not that nothing would occur (PMID 37086045).

Mechanism, receptor pharmacology and the biology of orexin signalling are covered separately in the PeptideU orexin learning course at /learn/orexin/; this page is limited to what published studies reported about adverse events and tolerability.

References

• Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis (Translational Psychiatry, 2025)
• Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis (Sleep Medicine Reviews, 2023)
• Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions (Expert Review of Neurotherapeutics, 2023)
• [Pharmacotherapies for insomnia] (La Revue du Praticien, 2024)
• Orexin Receptor Antagonists and Insomnia (Current Psychiatry Reports, 2022)
• Daridorexant for the Treatment of Insomnia (Health Psychology Research, 2022)
• The orexin story and orexin receptor antagonists for the treatment of insomnia (Journal of Sleep Research, 2023)
• Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery (Pharmacological Reviews, 2018)
• Treatment of Alzheimer Disease (Continuum, 2024)
• Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder (CNS Drugs, 2023)
• Long-term safety and efficacy of daridorexant in Japanese patients with insomnia disorder (Sleep Medicine, 2024)
• Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1 (New England Journal of Medicine, 2025)